Mode
Text Size
Log in / Sign up
Phase 3 N=40 Randomized Single-blind Treatment

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis

Osteoarthritis, Knee · Knee Pain

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score - Pain — 64.4; 62.5; 63.9; 13.2 score on a scale — p=0.594

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Micro Fragmented Adipose Tissue (Biological); Corticosteroid injection (Biological)
Age
Adult, Older Adult · 35+ yrs
Sex
All
Sponsor
Stanford University
Primary completion
Oct 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score - Pain
64.4; 62.5; 63.9; 13.2; 8.6; 12.0 0.594
PRIMARY
Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score - Symptoms
49.0; 47.5; 48.6; 4.5; 2.8; 4.1 0.847
SECONDARY
Lysholm Score
60.1; 63.3; 60.9; 10.1; 6.3; 9.1 0.633
SECONDARY
Veterans RAND 12 (VR-12) Score - Physical
42.9; 42.5; 42.8; 3.4; 4.6; 3.7 0.593
SECONDARY
Veterans RAND 12 (VR-12) Score - Mental
55.9; 58.7; 56.6; -1.6; -4.3; -2.3 0.480

Summary

This is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue versus conventional therapy of intra-articular injection of corticosteroid.

Eligibility Criteria

Inclusion Criteria

  • Age between 35 and 75 years-old
  • Diagnosis of pre-existing osteoarthritis of the joint by Kellgren-Lawrence Grade 2 or 3.
  • Working understanding of the English language and able to fully understand the procedure
  • Capable of providing informed consent
  • Able to complete online, in-person or phone surveys for the purposes of follow-up
  • Capable of understanding pre- and post-procedure care instructions
  • Ambulatory at baseline
  • Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and/or injections.

Exclusion Criteria

  • Age 75 years old
  • Radiographs demonstrating either no, little or severe osteoarthritis (Kellgren-Lawrence Grade 0, 1 )
  • Prior total or partial joint replacement surgery or a surgery involving cartilage regeneration (microfracture, ACI, etc)
  • Previous cortisone and/or Hyaluronic acid intra-articular injection within the last 3 months
  • Co-morbidity with rheumatologic condition, inflammatory arthritis
  • Currently undergoing immunomodulatory therapy
  • Uncontrolled endocrine disorder
  • BMI >35
  • Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and/or hepatitis C (HCV), infection and poorly controlled diabetes (HgA1C >7.0)
  • Pregnancy or planned pregnancy
  • previous stem cell injection into treatment joint
  • Patient scheduled to undergo any concomitant surgical procedures.
  • Coagulopathy or anticoagulant treatment
  • Chronic pain involving multiple body parts or opioid medication management
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03467919). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search